Soy protein (contains isoflavones) |
Fanti et al. 2006 [40] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 2:1
|
ESRD on haemodialysis. Primary disease 44% DM, 36% HTN, 20% other.
n = 32 participants; n = 19 IG; n = 13 CG. Attrition: 22% (n = 15 IG; n = 10 CG)
Mean age 61.0 ± 2.9 years; 40% female.
|
Chen et al. 2005 [42] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis. Primary diseases not described.
n = 42 participants; n = 18 IG; n = 19 CG (post attrition numbers). Attrition: 12%.
Participants divided into normolipidemic (n = 10 CG; n = 9 IG) and hyperlipidemic (n = 9 CG; n = 10 IG)
Mean age 59–66 ± 9–13 years; 92% female.
|
Chen et al. 2006 [41] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis and all with hypercholesterolaemia. Primary diseases not described.
n = 29 participants; n = 18 IG; n = 19 CG (post attrition numbers). Attrition: 11%.
Participants divided into normolipidemic (n = 13 CG; n = 13 IG) and hyperlipidemic (n = 9 CG; n = 10 IG)
Mean age 58–59 ± 11–12 years; 27% female.
|
Siefker & DiSilvestro 2006 [43] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis and all with hypercholesterolaemia. Primary diseases not described.
n = 20 participants; n = 8 IG; n = 9 CG (post attrition numbers). Attrition: 15%.
Mean age 20 years (range 27–77); 59% female.
|
Grape (contains various polyphenols) |
Janiques et al. 2014 [25] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis. Primary diseases not described.
n = 34 participants; n = 17 IG; n = 17 CG. Attrition: 6% (n = 16 IG; n = 16 CG).
Mean age 52.7–53.0 ± 9.8–13.7 years; 44% female.
|
Turmeric (contains curcuminoids) |
Pakfetrat et al. 2014 [38] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis, all with uremic pruritus. Primary diseases not described.
n = 100 participants; n = 50 IG; n = 50 CG. Attrition: 0%.
Mean age 51.0–55.6 ± 14.7–16.6 years; 40% female.
|
Pakfetrat et al. 2015 a [27] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis, all with uremic pruritus. Primary diseases: 35% DM, 33% HTN.
n = 50 participants; n = 50 IG; n = 50 CG. Attrition: 4%.
Mean age 47–52 ± 15 years; 45% female.
|
Cocoa (contains flavanols) |
Rassaf et al. 2016 [28] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis, all with uremic pruritus. Primary diseases: 32% HTN, 23% DM, 19% GN, 26% other.
n = 52 participants; n = 26 IG; n = 26 CG. Attrition: 6% (n = 24 IG; n = 25 CG).
Mean age 65 ± 13 years; 26% female.
|
Pomegranate (Phenolic acids & Flavanoids) |
Shema-Didi et al. 2012 [37] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 2:1
|
ESRD on haemodialysis. Primary diseases: 64% DM, 60% CVD.
n = 101 participants; n = 66 IG; n = 35 CG. Attrition: 34% (n = 41 IG; n = 26 CG).
Mean age 66–68 ± 11–13 years; 45% female.
|
Shema-Didi et al. 2014 [36] |
As per Shema-Didi et al. 2012 [37] |
Shema-Didi et al. 2012 [37] |
Shema-Didi et al. 2012 [37] |
Shema-Didi et al. 2013 [26] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial.
Allocation method: random allocation 2:1
|
ESRD on haemodialysis, receiving an iron transfusion during a single haemodialysis session. Primary diseases: 60% DM, 51% CVD. Others not described.
n = 27 participants; n = 17 IG; n = 10 CG. Attrition: N/A
Mean age 65–67 ± 11–13 years; 40% female.
|
Wu et al. 2015 [44] |
|
Two-arm parallel, placebo-controlled, double-blind randomised trial
Allocation method: random allocation 1:1
|
ESRD on haemodialysis. Primary diseases: 49% HTN, 36% DM. Others not described.
n = 33 participants; n = 16 IG; n = 17 CG. Attrition: 19% (n = 13 IG; n = 14 CG).
Mean age 53–56 ± 3 years; 39% female.
|